Bidwell Health
Can Latisse® Change Your Eye Color?
Latisse® can darken the iris, the colored part of the eye, and this change is likely permanent. The label does not give a reliable percentage for cosmetic upper-lash use. Eyelid skin darkening and changes in tissue around the eye are different risks.
What is the honest answer?
Bimatoprost can increase brown pigment in the iris, the colored part of the eye. This change is likely permanent and is not expected to reverse after stopping. The current Latisse label lists iris hyperpigmentation among additional reactions seen in clinical-trial experience. How often it happens with eyelash use is not reliably established. Changes may become noticeable over months to years and may go unnoticed at first. Uneven changes may leave the eyes different colors. The long-term effects of the increased pigment are unknown. Eye color and careful application do not guarantee protection. If you notice any change in iris color, stop using bimatoprost and contact an eye clinician. Do not restart until an eye clinician advises you.
Read the current label, sections 5.2 and 6.1 and patient information.
Why does glaucoma data get mentioned?
Glaucoma treatment places medication directly in the eye, often chronically, and the exposure pattern is different from cosmetic upper-lid application. That makes glaucoma data imperfect for predicting cosmetic-use risk. It is still relevant because it shows that bimatoprost can increase iris pigmentation under some exposure conditions.
Published eyelash studies did assess iris color, and a pooled analysis of six trials includes before-and-after eye photographs of reported cases. These limited data do not establish a reliable long-term rate. A small retrospective study found no iris changes in 50 cosmetic users, but that does not establish zero risk. Glaucoma-study percentages should not be used as a personal risk estimate for eyelash treatment.
Is eyelid darkening the same thing?
No. Eyelid skin darkening is different from iris color change. Eyelid darkening can happen where medication repeatedly touches the skin. It is generally considered more likely to improve after stopping than iris pigmentation, though patients should still report it.
How does Bidwell handle this risk?
A clinician reviews eye health and medicines before prescribing. If a permanent eye-color change would be unacceptable, do not start bimatoprost. Bidwell instructs patients to stop and contact an eye clinician if any iris-color change is noticed. This is our conservative approach to cosmetic treatment; stopping is not expected to reverse an established iris change.
You may take a baseline photograph and compare photographs monthly in similar lighting, without filters, as an optional way to notice changes. Home photographs cannot reliably rule out subtle changes, guarantee early detection or prevent permanent pigmentation. Do not wait for the next photograph if you notice a change. Tell anyone examining your eyes or checking your eye pressure that you use bimatoprost.
When should I stop and seek eye care?
Stop applying bimatoprost and seek prompt eye care for new eye pain, unusual redness, light sensitivity, swelling, discharge or signs of infection. Sudden vision loss, new flashes or floaters, or a shadow or curtain across vision need immediate eye care or an emergency department. Do not wait for an online message response.
National Eye Institute: flashes, floaters and a curtain over vision.
What should patients with hazel or green eyes know?
Increased brown pigmentation may be noticeable against a lighter or mixed-color iris. The label does not give a separate cosmetic-use percentage for each eye color. Neither having brown eyes nor careful application guarantees that pigment changes will not occur. Discuss how much this possibility matters to you before starting.
Can the risk be made zero?
No. Careful application can reduce unnecessary exposure, but it cannot make the risk zero. The safest application habits are upper-lid-only use, sterile applicators, no lower-lid application, blotting extra liquid, and stopping for concerning symptoms. Patients who are not comfortable with the residual risk should not start.
Frequently asked questions
Does Latisse always change eye color?
No. Bimatoprost can increase brown pigment in the iris, the colored part of the eye. This change is likely permanent and is not expected to reverse after stopping. The current Latisse label lists iris hyperpigmentation among additional reactions seen in clinical-trial experience. How often it happens with eyelash use is not reliably established. Changes may become noticeable over months to years and may go unnoticed at first. Uneven changes may leave the eyes different colors. The long-term effects of the increased pigment are unknown. Eye color and careful application do not guarantee protection. If you notice any change in iris color, stop using bimatoprost and contact an eye clinician. Do not restart until an eye clinician advises you.
Is eyelid darkening the same thing?
No. Eyelid darkening affects the skin; iris darkening affects the colored part of the eye. Skin darkening may improve after stopping, while iris changes are likely permanent.
Who should discuss eye-pressure medicines first?
Anyone using glaucoma or other pressure-lowering eye medicines needs the treating eye clinician’s guidance. Bimatoprost can interfere with the intended pressure-lowering effect of prostaglandin eye drops. Bidwell’s cosmetic service excludes prescription eye-drop use.
Can Latisse cause hollow-looking eyelids?
Loss of fat around the eye and a deeper eyelid crease have been reported after marketing. Their frequency cannot be reliably estimated from voluntary reports. Discuss new changes with the clinician.
What symptoms need immediate eye care?
Stop applying bimatoprost and seek prompt eye care for new eye pain, unusual redness, light sensitivity, swelling, discharge or signs of infection. Sudden vision loss, new flashes or floaters, or a shadow or curtain across vision need immediate eye care or an emergency department. Do not wait for an online message response.
Can it change the tissue around the eyes?
Yes. Postmarketing reports in the Latisse label include changes around the eye associated with fat loss, such as a deeper eyelid crease and lid drooping. Lash loss or breakage, allergic reactions and blurred vision have also been reported. Voluntary reports cannot establish how often these effects occur or prove the cause in every case. Tell your clinician about new changes; vision symptoms need prompt eye care. See section 6.2.
How common are irritation and redness?
The label’s four-month adult trial involved 278 participants. Its most frequently reported reactions included itching, redness, skin darkening, irritation, dry-eye symptoms and redness around the eyes, each in fewer than 4% of patients. Those figures should not be applied to permanent pigment changes or postmarketing fat-loss reports.
References
Related Bidwell pages
Latisse® is a registered trademark of AbbVie. Bidwell Health is not affiliated with, endorsed by, or sponsored by AbbVie. Bidwell does not sell or ship Latisse.